Rectal cancer stage II

4 trials 2 recruiting MedDRA PT
4 Registered trials
2 Recruiting
3 Unique sponsors
3 Unique IMPs
0 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Checkpoint inhibitor (PD-1) 1 substance
RAF/BRAF inhibitor 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Phase III: 2 Phase II: 2

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

2 trials
  • Institut Jules Bordet Academic
    IMP not specified
    2023-506703-26-00 1 country 2024 n=264
    Recruiting
  • Technische Universitat Dresden Academic
    IMP not specified
    2023-506715-18-00 2 countries 2019 n=140
    Ended

Phase II

2 trials
  • Institut Jules Bordet Academic
    NIVOLUMAB; REGORAFENIB
    2024-516554-22-00 1 country 2021 n=90
    Ended
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR Academic
    TISLELIZUMAB
    2025-522120-28-00 1 country 2026 n=67
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Institut Jules Bordet Academic 2 Phase II, Phase III 1
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR Academic 1 Phase II 1
Technische Universitat Dresden Academic 1 Phase III 0
New trials by year
2019
1
2021
1
2024
1
2026
1
← All indication landscapes